Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Laure Vincent; Luuk Gras; Patrice Ceballos; Jürgen Finke; Jakob Passweg; Stéphanie Harel; Laura Rosinol; Monique Minnema; Raphael Teipel; Jaap van Doesum; Mathias Hänel; Pascal Lenain; Carmen Botella-Garcia; Christian Koenecke; Sophie Ducastelle; Jaime Sanz; Wilfried Schroyens; Tsila Zuckerman; Federico Monaco; Linda Koster; Liesbeth de Wreede; Patrick J Hayden; Stefan Schönland; Ibrahim Yakoub-Agha; Meral Beksac

doi:10.1038/s41409-021-01560-y

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Laure Vincent, Luuk Gras, Patrice Ceballos, Jürgen Finke, Jakob Passweg, Stéphanie Harel, Laura Rosinol, Monique Minnema, Raphael Teipel, Jaap van Doesum, Mathias Hänel, Pascal Lenain, Carmen Botella-Garcia, Christian Koenecke, Sophie Ducastelle, Jaime Sanz, Wilfried Schroyens, Tsila Zuckerman, Federico Monaco, Linda KosterLiesbeth de Wreede, Patrick J Hayden, Stefan Schönland, Ibrahim Yakoub-Agha, Meral Beksac

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	499-501
Number of pages	3
Journal	Bone Marrow Transplantation
Volume	57
Issue number	3
Early online date	10 Jan 2022
DOIs	https://doi.org/10.1038/s41409-021-01560-y
Publication status	Published - Mar 2022

Access to Document

10.1038/s41409-021-01560-y

Cite this

Vincent, L., Gras, L., Ceballos, P., Finke, J., Passweg, J., Harel, S., Rosinol, L., Minnema, M., Teipel, R., van Doesum, J., Hänel, M., Lenain, P., Botella-Garcia, C., Koenecke, C., Ducastelle, S., Sanz, J., Schroyens, W., Zuckerman, T., Monaco, F., ... Beksac, M. (2022). Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplantation, 57(3), 499-501. https://doi.org/10.1038/s41409-021-01560-y

@article{6b995576c7cb4ccbbc29784198730eb1,

title = "Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT",

author = "Laure Vincent and Luuk Gras and Patrice Ceballos and J{\"u}rgen Finke and Jakob Passweg and St{\'e}phanie Harel and Laura Rosinol and Monique Minnema and Raphael Teipel and {van Doesum}, Jaap and Mathias H{\"a}nel and Pascal Lenain and Carmen Botella-Garcia and Christian Koenecke and Sophie Ducastelle and Jaime Sanz and Wilfried Schroyens and Tsila Zuckerman and Federico Monaco and Linda Koster and {de Wreede}, Liesbeth and Hayden, {Patrick J} and Stefan Sch{\"o}nland and Ibrahim Yakoub-Agha and Meral Beksac",

note = "Funding Information: We are grateful for all participating centers: Xavier Poir{\'e}, Cliniques Universitaires St. Luc, Brussels, Belgium; Nicolaas Schaap, Nijmegen Medical Center, Nijmegen, Netherlands; Jenny Byrne, Nottingham University, Nottingham, UK; Gandhi Damaj, CHU CAEN, Caen, France; Dries Deeren, AZ Delta, Roeselare, Belgium; Manos Nikolousis, Birmingham Heartlands Hospital, Birmingham, UK; Domenico Russo, USD Trapianti di Midollo, Adulti, Brescia, Italy; Joan Hendrik Veelken, Leiden University Hospital, Leiden, Netherlands; Claude Eric Bulabois, CHU Grenoble Alpes - Universit{\'e} Grenoble Alpes, Grenoble, France; Yves Chalandon, D{\'e}partement d{\textquoteright}Oncologie, Service d{\textquoteright}H{\'e}matologie, Geneva, Switzerland; Manuel Jurado Chac{\'o}n, Hospital Univ. Virgen de las Nieves, Granada, Spain; Sonja Martin, Robert Bosch Krankenhaus, Stuttgart, Germany; Josep Maria Ribera Santasusana, ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Simona Sica, Universita Cattolica S. Cuore, Rome, Italy.",

year = "2022",

month = mar,

doi = "10.1038/s41409-021-01560-y",

language = "English",

volume = "57",

pages = "499--501",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "3",

}

Vincent, L, Gras, L, Ceballos, P, Finke, J, Passweg, J, Harel, S, Rosinol, L, Minnema, M, Teipel, R, van Doesum, J, Hänel, M, Lenain, P, Botella-Garcia, C, Koenecke, C, Ducastelle, S, Sanz, J, Schroyens, W, Zuckerman, T, Monaco, F, Koster, L, de Wreede, L, Hayden, PJ, Schönland, S, Yakoub-Agha, I & Beksac, M 2022, 'Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT', Bone Marrow Transplantation, vol. 57, no. 3, pp. 499-501. https://doi.org/10.1038/s41409-021-01560-y

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. / Vincent, Laure; Gras, Luuk; Ceballos, Patrice et al.
In: Bone Marrow Transplantation, Vol. 57, No. 3, 03.2022, p. 499-501.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

AU - Vincent, Laure

AU - Gras, Luuk

AU - Ceballos, Patrice

AU - Finke, Jürgen

AU - Passweg, Jakob

AU - Harel, Stéphanie

AU - Rosinol, Laura

AU - Minnema, Monique

AU - Teipel, Raphael

AU - van Doesum, Jaap

AU - Hänel, Mathias

AU - Lenain, Pascal

AU - Botella-Garcia, Carmen

AU - Koenecke, Christian

AU - Ducastelle, Sophie

AU - Sanz, Jaime

AU - Schroyens, Wilfried

AU - Zuckerman, Tsila

AU - Monaco, Federico

AU - Koster, Linda

AU - de Wreede, Liesbeth

AU - Hayden, Patrick J

AU - Schönland, Stefan

AU - Yakoub-Agha, Ibrahim

AU - Beksac, Meral

N1 - Funding Information: We are grateful for all participating centers: Xavier Poiré, Cliniques Universitaires St. Luc, Brussels, Belgium; Nicolaas Schaap, Nijmegen Medical Center, Nijmegen, Netherlands; Jenny Byrne, Nottingham University, Nottingham, UK; Gandhi Damaj, CHU CAEN, Caen, France; Dries Deeren, AZ Delta, Roeselare, Belgium; Manos Nikolousis, Birmingham Heartlands Hospital, Birmingham, UK; Domenico Russo, USD Trapianti di Midollo, Adulti, Brescia, Italy; Joan Hendrik Veelken, Leiden University Hospital, Leiden, Netherlands; Claude Eric Bulabois, CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France; Yves Chalandon, Département d’Oncologie, Service d’Hématologie, Geneva, Switzerland; Manuel Jurado Chacón, Hospital Univ. Virgen de las Nieves, Granada, Spain; Sonja Martin, Robert Bosch Krankenhaus, Stuttgart, Germany; Josep Maria Ribera Santasusana, ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Simona Sica, Universita Cattolica S. Cuore, Rome, Italy.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85122675886&partnerID=8YFLogxK

U2 - 10.1038/s41409-021-01560-y

DO - 10.1038/s41409-021-01560-y

M3 - Letter

C2 - 35013536

SN - 0268-3369

VL - 57

SP - 499

EP - 501

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 3

ER -

Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S et al. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplantation. 2022 Mar;57(3):499-501. Epub 2022 Jan 10. doi: 10.1038/s41409-021-01560-y

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Access to Document

Other files and links

Cite this